ArticleFrontiers in medicine2025
An integrated machine learning framework for developing and validating diagnostic models and drug predictions based on ulcerative colitis genes.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a long-lasting inflammatory bowel disease that causes inflammation in the intestines and triggers autoimmune responses. This study aims to identify immune-related biomarkers for ulcerative colitis (UC) and explore potential therapeutic targets. First, we downloaded the expression profiles of datasets GSE87466, GSE87473, and GSE92415 from the GEO database. Next, we identified differentially expressed genes (DEGs) that are associated with UC. Using the WGCNA algorithm, we screened key module genes in UC and retrieved immune-related genes (IRGs) from the ImmPort database. We identified immune-related differentially expressed genes by intersecting the results from WGCNA, DEGs, and IRGs. To build a diagnostic model for UC, we applied 113 combinations of 12 machine learning algorithms. This included 10-fold cross-validation on the training set and external validation on the test set. The single-cell results presented the cellular profile of UC and indicated that the key genes were significantly associated with macrophages, epithelial cells, and fibroblasts. The single-cell results presented the cell atlas of UC and suggested that key genes were significantly associated with macrophages, epithelial cells and fibroblasts. Quantitative polymerase chain reaction (q-PCR) was used to verify the expression levels of the core biomarkers screened out by machine learning. We conducted enrichment analysis using Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA), which showed biological processes and signaling pathways associated with UC. Immune cell infiltration analysis based on CIBERSORT was also performed. We also screened potential drugs from the DSigDB drug database. To evaluate their effectiveness, we performed molecular docking and dynamics simulations. The results suggested that compounds like thalidomide and troglitazone are promising candidates for new UC drug development. Our findings provide insights into the pathogenesis of UC, its clinical treatment, and potential drug development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.